HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flom-Halvorsen, H. I. Articles by Brosstad, F. Search for Related Content PubMed PubMed Citation Articles by Flom-Halvorsen, H. I. Articles by Brosstad, F. Related Collections Related Article

Ann Thorac Surg 1999;67:1012-1016
© 1999 The Society of Thoracic Surgeons

---

Original Articles

Assessment of heparin anticoagulation: comparison of two commercially available methods

^a Research Institute for Internal Medicine, University of Oslo, Rikshospitalet, Oslo, Norway
^b Oslo Heart Center, Oslo, Norway

Accepted for publication September 25, 1998.

Address reprint requests to Dr Øvrum, Oslo Heart Center, Pilestredet 32, N-0027 Oslo, Norway

Background. The activated clotting time is a bedside method routinely used to monitor heparin anticoagulation during operations requiring cardiopulmonary bypass. The thrombolytic assessment system heparin management test is a new bedside method for monitoring heparin effect. We compared these methods with respect to their ability to reflect the actual heparin concentration in plasma determined by an anti-FXa method.

Methods. Two studies were done, an ex vivo study on ten patients who had coronary artery bypass using nonheparin-coated cardiopulmonary bypass circuits and full systemic heparinization and an in vitro study on single donor plasma spiked with heparin 0 to 10 IU/mL.

Results. Ex vivo study correlation coefficients of activated clotting time and the thrombolytic assessment system heparin management test clotting times versus anti-FXa-based heparin assay were low (r = 0.53, p = 0.002/r = 0.64, p < 0.001) in contrast with the corresponding correlation coefficients for the in vitro study (r = 0.98, p < 0.001/r = 0.99, p < 0.001). A substantial variability in duplicate activated clotting time determinations was noted, which was less pronounced with the thrombolytic assessment system heparin management test.

Conclusions. The thrombolytic assessment system method does not correlate better to the actual amount of heparin during cardiopulmonary bypass procedures than the activated clotting time method, which should be performed in duplicate.

Related Article

Benjamin P. Bidstrup
Ann. Thorac. Surg. 1999 67: 1016-1017. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				S. A Spinler, A. K Wittkowsky, E. A Nutescu, and M. A Smythe Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin Ann. Pharmacother., July 1, 2005; 39(7): 1275 - 1285. [Abstract] [Full Text] [PDF]

				E. Ovrum, G. Tangen, R. Oystese, M. A. L. Ringdal, and R. Istad Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0324 - 330. [Abstract] [Full Text] [PDF]